TXG earnings / call / takeaways

TXG earnings call: key takeaways

What TXG said on its earnings call of November 5, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 5, 2026·AI-generated from the call transcript and Lician data

TXG reported revenue of $150.7 million for Q3 2026, exceeding the $147.8 million consensus estimate (14:41)
The company raised its full-year revenue guidance to $625 million to $635 million, up from $610 million to $630 million (16:38)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	-$0.29	–	–
Revenue	$147.8M	–	–

What changed since last quarter

The company raised full-year revenue guidance, citing stronger-than-anticipated spatial consumables and Atera shipment outlook. (16:38)
Atera production ramp is progressing well, with 50 units expected to be shipped by year-end, up from 40. (16:38)
Gross margins are expected to step down sequentially in Q4 due to Atera shipments, but the platform's gross margin profile is superior to Xenium. (32:57)

Guidance

Metric	This call	Previous call
Revenue	Full-year revenue of $625 million to $635 million. (16:38)	not captured

What analysts pressed on

How will gross margins recover post-Atera launch? (32:57)
What is the mix of whole transcriptome versus select runs for Atera? (31:04)
How will the transition to APEX impact top-line revenue? (28:59)

In their words

We're seeing extensive demand for Atero across universities, academic medical centers, and biopharma. Serge Saxonov (3:50)
The success we're seeing with ATER is a powerful demonstration of this trend. Serge Saxonov (2:14)
We built ATERRA as a long duration, upgradeable platform to keep expanding what's possible in spatial biology. Serge Saxonov (5:20)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.